Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation

被引：9

作者：

Miyazaki, Kunihiko ^{[1
]}

Tamura, Tomohiro ^{[2
]}

Kaburagi, Takayuki ^{[2
]}

Saito, Kazuhito ^{[3
,4
]}

Inagaki, Masaharu ^{[3
,4
]}

Yamashita, Takaaki ^{[5
]}

Ichimura, Hideo ^{[6
,7
]}

Nawa, Takeshi ^{[6
,7
]}

Endo, Takeo ^{[8
]}

Hayashihara, Kenji ^{[9
]}

Kimura, Masaki ^{[10
]}

Kurishima, Koichi ^{[11
]}

Nakamura, Hiroyuki ^{[12
,13
]}

Furukawa, Kinya ^{[12
,13
]}

Kikuchi, Norihiro ^{[14
]}

Satoh, Hiroaki ^{[15
]}

Hizawa, Nobuyuki ^{[16
]}

机构：

[1] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan

[2] Ibaraki Cent Hosp, Resp Ctr, Kasama, Ibaraki, Japan

[3] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[4] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan

[5] JA Toride Med Ctr, Div Resp Med, Toride, Japan

[6] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan

[7] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan

[8] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[9] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan

[10] Tsukuba Mem Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[11] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[12] Tokyo Med Univ, Div Resp Med, Ibaraki Med Ctr, Ami Machi, Tokyo, Japan

[13] Tokyo Med Univ, Div Thorac Surg, Ibaraki Med Ctr, Ami Machi, Tokyo, Japan

[14] Kasumigaura Med Ctr, Div Resp Med, Tsuchiura, Ibaraki, Japan

[15] Univ Tsukuba, Mito Med Ctr, Mito Kyodo Gen Hosp, Div Resp Med, Mito, Ibaraki, Japan

[16] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan

来源：

ANTICANCER RESEARCH | 2018年 / 38卷 / 09期

关键词：

Clinical practice; afatinib; non-small cell lung cancer; acquired T790M mutation; osimertinib; immune-checkpoint inhibitor; CELL LUNG-CANCER; 1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB; ADENOCARCINOMA; OSIMERTINIB; EXPERIENCE; ERLOTINIB; RECEPTOR;

D O I：

10.21873/anticanres.12871

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To describe real clinical outcomes when using afatinib therapy to treat non-small cell lung cancer patients who have an acquired EGFR T790M mutation. Materials and Methods: A retrospective chart review was conducted from January 2013 to November 2017 sourced from 15 medical institutes that cover a population of three million people. Results: There were 74 patients who met the above-mentioned criteria. Treatment outcomes with afatinib, in patients with or without tyrosine kinase inhibitor (TKI) therapy prior to afatinib, were similar to previously reported clinical trials. Stratification of patients by the presence or absence of TKI pretreatment before afatinib, and the presence or absence of an acquired T790M mutation found no statistical difference in overall survival. Conclusion: This population-based study found that the disadvantages of pretreatment before afatinib, and absence of an acquired T790M EGFR mutation, could be overcome by an appropriate treatment strategy in clinical practice.

引用

页码：5409 / 5415

页数：7

共 19 条

[1] Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial [J].

Akamatsu, Hiroaki ;

Katakami, Nobuyuki ;

Okamoto, Isamu ;

Kato, Terufumi ;

Kim, Young Hak ;

Imamura, Fumio ;

Shinkai, Masaharu ;

Hodge, Rachel A. ;

Uchida, Hirohiko ;

Hida, Toyoaki .

CANCER SCIENCE, 2018, 109 (06) :1930-1938

[2]

[Anonymous], LANCET ONCOL

[3] Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea [J].

Choi, Moon Ki ;

Ahn, Jin Seok ;

Kim, Young-Chul ;

Cho, Byoung Chul ;

Oh, In-Jae ;

Kim, Sang-We ;

Lee, Jong Seok ;

Kim, Joo-Hang ;

Ahn, Myung-Ju ;

Park, Keunchil .

LUNG CANCER, 2018, 119 :36-41

[4] Acquired EGFR T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study [J].

Kaburagi, Takayuki ;

Kiyoshima, Moriyuki ;

Nawa, Takeshi ;

Ichimura, Hideo ;

Saito, Takefumi ;

Hayashihara, Kenji ;

Yamada, Hideyasu ;

Satoh, Hiroaki ;

Endo, Takeo ;

Inage, Yoshihisa ;

Saito, Kazuhito ;

Inagaki, Masaharu ;

Hizawa, Nobuyuki ;

Sato, Yukio ;

Ishikawa, Hiroichi ;

Sakai, Mitsuaki ;

Kamiyama, Koichi ;

Kikuchi, Norihiro ;

Nakamura, Hiroyuki ;

Furukawa, Kinya ;

Kodama, Takahide ;

Yamashita, Takaaki ;

Nomura, Akihiro ;

Yoshida, Susumu .

ANTICANCER RESEARCH, 2018, 38 (05) :3145-3150

[5] LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both [J].

Katakami, Nobuyuki ;

Atagi, Shinji ;

Goto, Koichi ;

Hida, Toyoaki ;

Horai, Takeshi ;

Inoue, Akira ;

Ichinose, Yukito ;

Koboyashi, Kunihiko ;

Takeda, Koji ;

Kiura, Katsuyuki ;

Nishio, Kazuto ;

Seki, Yoko ;

Ebisawa, Ryuichi ;

Shahidi, Mehdi ;

Yamamoto, Nobuyuki .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (27) :3335-+

[6] Osimertinib: A Review in T790M-Positive Advanced Non-Small Cell Lung Cancer [J].

Lamb, Yvette N. ;

Scott, Lesley J. .

TARGETED ONCOLOGY, 2017, 12 (04) :555-562

[7] Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma [J].

Liang, Sheng-Kai ;

Hsieh, Min-Shu ;

Lee, Meng-Rui ;

Keng, Li-Ta ;

Ko, Jen-Chung ;

Shih, Jin-Yuan .

ONCOTARGET, 2017, 8 (52) :90430-90443

[8] Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for thetreatment of advanced non-small-cell lung cancer [J].

Marquez-Medina, Diego ;

Popat, Sanjay .

FUTURE ONCOLOGY, 2015, 11 (18) :2525-2540

[9] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[10] Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial [J].

Park, Keunchil ;

Tan, Eng-Huat ;

O'Byrne, Ken ;

Zhang, Li ;

Boyer, Michael ;

Mok, Tony ;

Hirsh, Vera ;

Yang, James Chih-Hsin ;

Lee, Ki Hyeong ;

Lu, Shun ;

Shi, Yuankai ;

Kim, Sang-We ;

Laskin, Janessa ;

Kim, Dong-Wan ;

Arvis, Catherine Dubos ;

Kolbeck, Arvis Karl ;

Laurie, Scott A. ;

Tsai, Chun-Ming ;

Shahidi, Mehdi ;

Kim, Miyoung ;

Massey, Dan ;

Zazulina, Victoria ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2016, 17 (05) :577-589

← 1 2 →